Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PROCEPT BioRoboticsPRCT +3.44%70 Net Cash per Share is $1.87 as of Mar. 2026, which is 88% below its 10-year median of 16.00. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $94.52 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 302 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks worse than 54.97% on this metric.
The historical rank and industry rank for PROCEPT BioRobotics's Net Cash per Share or its related term are showing as below:
PRCT'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.66 Med: 16 Max: 65.67
Current: 9.96
During the past 7 years, the highest Price-to-Net-Cash Ratio of PROCEPT BioRobotics was 65.67. The lowest was 4.66. And the median was 16.00.
PRCT's Price-to-Net-Cash is ranked worse than 54.97% of 302
companies
in the Medical Devices & Instruments industry
Industry Median: 7.605
vs PRCT: 9.96
PROCEPT BioRobotics (NAS:PRCT) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
PROCEPT BioRobotics Net Cash per Share Related Terms
PROCEPT BioRobotics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRCT vs INMD, LMRI, QDEL: Net Cash per Share Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Price-to-Net-Cash falls into.
PROCEPT BioRobotics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
PROCEPT BioRobotics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROCEPT BioRobotics (PRCT) has a Net Cash per Share of $1.87 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on PROCEPT BioRobotics and its competitors. This is 88% below median its historical median of 16.00. Over the past decade, PROCEPT BioRobotics' Net Cash per Share has ranged from 4.66 to 65.67. According to the industry distribution chart, PROCEPT BioRobotics ranks #166 out of 302 companies in the Medical Devices & Instruments industry, placing it in the top 55%.
Is PROCEPT BioRobotics' Net Cash per Share too high?
PROCEPT BioRobotics' current Net Cash per Share of $1.87 is 88% below median its 10-year median of 16.00. Over the past 10 years, this metric has ranged from a low of 4.66 to a high of 65.67. The Medical Devices & Instruments industry median Net Cash per Share is 7.61. PROCEPT BioRobotics' value of $1.87 is 75.4% below this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #166 out of 302 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Net Cash per Share compare to INMD and LMRI?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #166 out of 302 companies for Net Cash per Share. This places PROCEPT BioRobotics in the lower half of its industry. The industry median Net Cash per Share is 7.61. PROCEPT BioRobotics' value of $1.87 is 75.4% below this benchmark. Historically, PROCEPT BioRobotics' own Net Cash per Share has ranged from 4.66 to 65.67 over the past decade. While the company's 10-year median is 16.00 vs. the industry median of 7.61, PROCEPT BioRobotics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 7.61, based on 302 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current Net Cash per Share of $1.87 is 75.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 7.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Net Cash per Share is $1.87, which is 88% below median its own 10-year median of 16.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $94.52, compared to a current price of $18.62 — trading 80.3% below its estimated fair value. The current Net Cash per Share is $1.87, which is 88% below median its 10-year median of 16.00 and 75.4% below the Medical Devices & Instruments industry median of 7.61. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Net Cash per Share is $1.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $18.62 is trading 80.3% below its estimated GF Value™ of $94.52.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
Net Cash per Share: $1.87 (88% below median its 10-year median of 16.00)
GF Value™: $94.52 vs. price of $18.62 (80.3% below fair value)
Industry Position: 75.4% below the Medical Devices & Instruments median (#166 of 302)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
